Grifols prepares for late-stage plans with plasma-derived medicines in 2024 - Pharmaceutical Technology (2024)

  • News

In an interview with Pharmaceutical Technology, the company’s chief scientific officer detailed the company’s upcoming 2024 plans.

Akosua Mireku February 28, 2024

Grifols prepares for late-stage plans with plasma-derived medicines in 2024 - Pharmaceutical Technology (1)

Grifols plans to release Phase III results of its long-term albumin treatment designed to increase survival time in patients with decompensated cirrhosis and ascites in 2024, says chief scientific innovations officer Jörg Schüttrumpf.

Free Report

How is the Biopharmaceutical industry evolving?

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape.GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.Access the report to:

  • Benchmark the impact of major themes on the Biopharmaceutical industry.
  • Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
  • Evaluate the effects of COVID-19 on the sector.

Download the full report to understand what to expect and how to align your strategies for success.

Thank you.

You will receive an email shortly. Please check your inbox to download the Report.

By GlobalData

Grifols prepares for late-stage plans with plasma-derived medicines in 2024 - Pharmaceutical Technology (4)

In an exclusive interview with Pharmaceutical Technology, Schüttrumpf outlined the plasma derived-medicines company’s 2024 goals for its late-stage candidates as several trials come to a head. The aforementioned Preciosa trial (NCT03451292) studying human albumin is focused on patients awaiting a suitable transplant.

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Grifols prepares for late-stage plans with plasma-derived medicines in 2024 - Pharmaceutical Technology (5)

Company Profile – free sample

Your download email will arrive shortly

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Grifols also plans to release data from its Phase III ESsCAPE study (NCT05722938), investigating trimodulin, triple action immunoglobulin with IgM, IgA and IgG, at some point this year.

In February, the company reported positive efficacy results from a trial investigating Grifols’ fibrinogen concentrate (FC), BT524, for the treatment of acquired fibrinogen deficiency (AFD). The company now plans to complete European Medicines Agency (EMA) and US Food and Drug Administration (FDA) regulatory submissions, in pursuit of approval.

Additionally, the Spain-headquartered company is exploring partnerships similar to the one it has with Ethicon, says Schüttrumpf. Grifols began its collaboration with Ethicon, a subsidiary of Johnson & Johnson, in 2017, wherein Grifols agreed to exclusively manufacture and supply plasma-derived products for use in the biosurgery field for 10 years.

See Also:

  • Boehringer kickstarts two Phase III trials as MASH therapy wins breakthrough status

In 2021, Grifols announced the acquisition of Tiancheng (Germany) Pharmaceutical Holdings, which owned 89.88% of another plasma products specialist Biotest. Grifols is developing trimodulin and BT524 with Biotest. Before the acquisition, Grifols had already explored fibrinogen concentrate for the development of Vistaseal (fibrinogen (human) + thrombin (human), commercialised as Veraseal in Europe.

Schüttrumpf highlights Grifols’ ability to complete in-house manufacturing for plasma-derived therapeutics like BT524. He said that this gave the company a major advantage in its operations, also allowing it to offer its manufacturing services to other pharmaceutical companies. “We are working with different partners. In the immunology, and pulmonary disease space, to support their growth,” says Schüttrumpf.

Grifols has plans to release its 2023 annual financial report on 29 February.

Free Report

How is the Biopharmaceutical industry evolving?

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape.GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.Access the report to:

  • Benchmark the impact of major themes on the Biopharmaceutical industry.
  • Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
  • Evaluate the effects of COVID-19 on the sector.

Download the full report to understand what to expect and how to align your strategies for success.

Thank you.

You will receive an email shortly. Please check your inbox to download the Report.

By GlobalData

Grifols prepares for late-stage plans with plasma-derived medicines in 2024 - Pharmaceutical Technology (7)

Grifols prepares for late-stage plans with plasma-derived medicines in 2024 - Pharmaceutical Technology (8)

Sign up for our daily news round-up!

Give your business an edge with our leading industry insights.

Sign up

Grifols prepares for late-stage plans with plasma-derived medicines in 2024 - Pharmaceutical Technology (2024)

References

Top Articles
Latest Posts
Recommended Articles
Article information

Author: Prof. Nancy Dach

Last Updated:

Views: 6614

Rating: 4.7 / 5 (77 voted)

Reviews: 92% of readers found this page helpful

Author information

Name: Prof. Nancy Dach

Birthday: 1993-08-23

Address: 569 Waelchi Ports, South Blainebury, LA 11589

Phone: +9958996486049

Job: Sales Manager

Hobby: Web surfing, Scuba diving, Mountaineering, Writing, Sailing, Dance, Blacksmithing

Introduction: My name is Prof. Nancy Dach, I am a lively, joyous, courageous, lovely, tender, charming, open person who loves writing and wants to share my knowledge and understanding with you.